On June 19 in Tel Aviv, Vietnam Gene and Cell Technology Joint Stock Company (VGCT) officially inaugurated its Research and Application Center in Israel, aiming to connect and promote cooperation, technology transfer, and production applications with Israel’s innovative and high-tech market.
During the opening ceremony, a Memorandum of Understanding (MOU) was signed between VGCT, a member company of CT Group, and OBCT-CD24, focusing on breakthrough scientific solutions for treating lung diseases.
These are VGCT’s first Israeli partners, marking an important step toward strengthening collaboration and applying advanced technologies in key business sectors. This aligns with the Group’s strategy of transforming its investment–business model and building strong connections with innovative, high-tech markets such as Israel.
The establishment of the Research and Application Center, as well as the strategic cooperation between VGCT and its Israeli partner, holds significant meaning. It reaffirms the company’s strategy of innovation in investment and business models, prioritizing the development of high-tech sectors to keep pace with the rapid progress of the global scientific and technological revolution, while fostering connections between CT Group and Israel – a market rich in strengths and potential for collaboration in innovation and advanced technology.
